Interferon β-1b Treatment In a Korean Girl with Multiple Sclerosis

다발성 경화증 환아에서 Interferon β-1b의 효과적인 치료 증례

인터페론 베타는 성인 다발성 경화증 환자에서 질병의 경과를 호전시키고 재발을 방지하는 효과가 있어서 널리 사용되고 있다. 소아에서는 안정성 및 효과가 잘 정립되어 있지는 않으나 최근 연구결과들에 따르면 소아의 다발성 경화증에서도 Interferon β-1b와 같은 disease modifying therapies (DMTs)를 초기에 사용하도록 권고하고 있다. 저자들은 다발성 경화증으로 진단된 13세 여자 환자에서 3년간 Interferon β-1b를 사용하여 부작용과 재발 없이 효과적으로 치료 하였기에 이를 보고하는 바이다.

Here we report a case of pediatric multiple sclerosis treated with interferon β-1b. lnterferon beta is widely used in adult patients with multiple sclerosis (MS). However. its effects and safety in pediatric patients have not been well established. Although supporting data are limited. the use of disease modifying therapies (DMTs) such as interferon β-1b is recommended early in treatment of children with MS. Reports of interferon beta treatment in pediatric MS patients in Korea are rare. In this report. we describe a Korean girl who was effectively treated with interferon β-1b for three years. There were no relapses or serious side effects. Therefore. this report provides evidence supporting the use of interferon beta in pediatric MS patients in Korea and other Asian countries. We also reviewed current medical treatment of MS. including some DMTs and second-line treatment options such as natalizumab and cyclophosphamide. and several new oral agents such as fingolimod.